Back to top
more

BioLineRx (BLRX)

(Delayed Data from NSDQ)

$0.45 USD

0.45
441,193

+0.01 (3.17%)

Updated Nov 6, 2024 03:59 PM ET

After-Market: $0.45 0.00 (-0.66%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

New Strong Sell Stocks for June 4th

by Zacks Equity Research

ASLN, BLRX, FLXN, ICMB, and MRNS have been added to the Zacks Rank #5 (Strong Sell) List on June 4, 2021.

Aclaris (ACRS) Up on Preliminary Data for MK2 Inhibitor in RA

by Zacks Equity Research

Aclaris (ACRS) posts favorable preliminary topline results from a phase IIa study evaluating its investigational oral candidate ATI-450 for treating moderate to severe rheumatoid arthritis. Shares up.

RedHill's (RDHL) RHB-204 Gets FDA Fast Track Designation

by Zacks Equity Research

RedHill (RDHL) gets Fast Track status from the FDA for the treatment of nontuberculous mycobacteria (NTM) disease.

Altimmune (ALT) Begins Phase II Study for Chronic Hepatitis B

by Zacks Equity Research

Altimmune (ALT) enrolls the first patient in a phase II study evaluating HepTcell for the treatment of patients with chronic hepatitis B. Shares rise.

Nektar (NKTR) Begins Dosing in NKTR-255 Study for Two Cancers

by Zacks Equity Research

Nektar (NKTR) doses the first patient in a phase I/II study on NKTR-255 in combination with Erbitux for treating head and neck squamous cell carcinoma or colorectal cancer. Shares up.

Fusion Pharmaceuticals (FUSN) Jumps: Stock Rises 9%

by Zacks Equity Research

Fusion Pharmaceuticals (FUSN) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Pacira (PCRX) Gets European Commission Approval for Exparel

by Zacks Equity Research

The EC approves Pacira's (PCRX) Exparel for treating post-operative pain in adults and as a field block for treating somatic post-operative pain from small- to medium-sized surgical wounds in adults.

Aerie (AERI) Gets Positive CHMP Opinion for Roclanda in EU

by Zacks Equity Research

Aerie (AERI) receives positive CHMP opinion for Roclanda for reduction of elevated intraocular pressure in adult patients.

Zoetis (ZTS) Librela Gets Marketing Authorization in Europe

by Zacks Equity Research

Zoetis (ZTS) gets marketing authorization for Librela, for monthly alleviation of osteoarthritis pain in dogs.

Merck's (MRK) Keytruda Combo Meets Goal in Kidney Cancer Study

by Zacks Equity Research

Merck (MRK) and partner Eisai report positive top-line data from the phase III study evaluating Keytruda plus the latter's Lenvima for first-line treatment of patients with kidney cancer.

ChemoCentryx (CCXI) Reports Wider-Than-Expected Q3 Loss

by Zacks Equity Research

ChemoCentryx (CCXI) reports a wider-than-expected Q3 loss and misses sales estimates in the third quarter of 2020.

Catalyst's (CPRX) Q3 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Catalyst (CPRX) beats on earnings but misses sales estimates in the third quarter of 2020.

Sarepta (SRPT) Q3 Loss Widens Y/Y, Revenues Beat Estimates

by Zacks Equity Research

Sarepta (SRPT) Q3 revenues increase year over year.

Aerie (AERI) Q3 Loss Narrower Than Expected, Sales Rise Y/Y

by Zacks Equity Research

Aerie (AERI) reports a narrower-than-expected loss and revenues beat estimates in the third quarter of 2020.

Amarin's (AMRN) Q3 Earnings Lag, Sales In Line, Stock Down

by Zacks Equity Research

Amarin's (AMRN) revenue growth in the third quarter is attributable to continued demand for its cardiovascular drug, Vascepa. Generic competition for Vascepa seems imminent.

Perrigo (PRGO) Q3 Earnings Beat, Revenues Miss, Stock Up

by Zacks Equity Research

Perrigo (PRGO) reports decent third-quarter 2020 results. U.S. consumer self-care segment drives sales. Recovery in other two segments encouraging.

Heron's (HRTX) Pain Drug Zynrelef Gets EU Approval, Shares Up

by Zacks Equity Research

Heron's (HRTX) Zynrelef gains a marketing nod from the European Commission for managing postoperative pain in surgical wounds among adult patients. Stock rises.

Radius Completes Enrollment in Phase III Osteoporosis Study

by Zacks Equity Research

Radius (RDUS) completes enrollment in its phase III study assessing a wearable abaloparatide-transdermal patch in the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Savara to Stop Study on Molgradex for NTM Lung Infection

by Zacks Equity Research

Savara (SVRA) to halt the ENCORE study on its lead candidate Molgradex, which was meant to treat nontuberculous mycobacterial (NTM) lung infection in people living with cystic fibrosis.

Onconova's Cancer Study Fails to Meet Endpoint, Shares Down

by Zacks Equity Research

Onconova's (ONTX) shares fall more than 60% after its phase III study on intravenous rigosertib in patients with higher-risk myelodysplastic syndromes did not meet the primary endpoint.

Avenue Therapeutics (ATXI) Misses Earnings Estimates in Q2

by Zacks Equity Research

Avenue Therapeutics (ATXI) reports a wider-than-expected loss in the second quarter of 2021.

Catalyst's (CPRX) Q2 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Catalyst (CPRX) beats both earnings and sales estimates in the second quarter of 2020.

Pacira's (PCRX) Q2 Earnings Miss Estimates, Revenues In Line

by Zacks Equity Research

Pacira (PCRX) misses on earnings for the second quarter of 2020 while its revenues meet the mark.

Corcept (CORT) Q2 Earnings Top Estimates, Revenues Miss Mark

by Zacks Equity Research

Corcept's (CORT) earnings trump estimates for the second quarter of 2020 while revenues fall shy of the same.

BioLineRx (BLRX) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

BioLineRx (BLRX) will provide updates on its clinical programs when it releases second-quarter 2020 results.